Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GYKI 14451

Known as: GYKI 14,451, GYKI-14,451, GYKI-14451 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Newly developed synthetic and recombinant thrombin inhibitors possess strong anticoagulant effects. Despite these effects… Expand
Is this relevant?
1992
1992
A series of peptide aldehydes synthetized in our institute during the last 15 years were screened to detect their inhibitory… Expand
Is this relevant?
1990
1990
D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent… Expand
Is this relevant?
1984
1984
The search for new compounds active in blood coagulation with different properties to classical anticoagulants, e.g. heparin, has… Expand
Is this relevant?
1982
1982
Inhibition of blood coagulation by peptide aldehydes has been studied. Amino acid sequences were assembled from the P1-P2 portion… Expand
Is this relevant?
1981
1981
Summary The in vitro effects of a new synthetic tripeptide GYK1 14,451 on platelet aggregation and arachidonic acid metabolism… Expand
Is this relevant?
1981
1981
Abstract Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4… Expand
Is this relevant?
Review
1980
Review
1980
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet… Expand
Is this relevant?